
Ipamorelin
Selective peptide studied for growth-hormone release with limited effects on other hormones.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
Ipamorelin is a small peptide that activates the ghrelin receptor, a signal involved in growth-hormone release. It is studied because research models show a more selective growth-hormone response, with less effect on hormones such as cortisol and prolactin. Researchers examine its effects on hormone patterns, recovery, and body composition.
Why researchers reach for Ipamorelin
Selective GH release
Minimal impact on cortisol and prolactin in preclinical data.
Short pulsatile profile
Half-life supports pulse-mimicking protocols.
Pairs with GHRH analogues
Standard comparator with CJC-1295 in research.
Key features
- ≥99% HPLC purity
- Pentapeptide ghrelin-receptor agonist
- Mass-spec verified
- Cold-chain dispatch
How it works
GHS-R1a agonism
Selectively activates the ghrelin receptor on somatotrophs.
GH pulse induction
Triggers a short, physiologic GH pulse.
Clean profile
Does not meaningfully engage ACTH or prolactin pathways.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Typical reconstitution | 2 mL bacteriostatic water | Yields 2.5 mg/mL (2500 mcg/mL) |
| Reported research range | 200–300 mcg per dose | Reference only |
Tracking this compound? Registered researchers can log active Ipamorelin protocols in their private Research Log.
Timing in research protocols
Evening or pre-exercise windows in study designs, based on growth-hormone physiology rather than a timing trial.
- No registered human trial has compared times of day for ipamorelin specifically; the original pharmacology work (Raun et al., 1998) is in swine and rat pituitary models.
- Secondary pharmacokinetic summaries report a short profile — peak around 15–30 minutes, half-life near 2 hours — which is why study protocols cluster doses rather than spacing them widely.
- Fasted, low-somatostatin windows such as before sleep are favoured in protocols because food intake, particularly carbohydrate and fat, blunts endogenous growth-hormone pulses.
- Cycle lengths reported in the literature are not standardised.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular weight
- 711.86 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 5 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on Ipamorelin. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
